FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:836-839 August 25, 2005 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Vincenti, F. PubMed Citation

The success of organ transplantation owes much to improvements in the immunosuppressive regimens that prevent or suppress allograft rejection. Nevertheless, the potent immunosuppressive drugs that are now in general use increase susceptibility to infection and cancer and can also have adverse effects not directly related to immunosuppression.

Conventional immunosuppressive agents affect not only immune cells but also other cells. Glucocorticoids, for example, can cause a myriad of side effects,¹ but these harmful actions are often minimized by combining glucocorticoids with other immunosuppressive medications. In use since the early days of transplantation, small-molecule immunosuppressive drugs act by targeting DNA or proteins . . . [Full Text of this Article]

This article has been cited by other articles:

• Tattevin, P., Le Tulzo, Y., Schwartz, S., Ruhnke, M., Ribaud, P., Corey, L., Driscoll, T., Cornely, O. A., Schuler, U., Lutsar, I., Troke, P., Thiel, E. (2006). Improved outcome in central nervous system aspergillosis. Blood 107: 3410-3412 [Full Text]  
• TAMLER, R., EPSTEIN, S. (2006). Nonsteroid Immune Modulators and Bone Disease. Ann. N. Y. Acad. Sci. 1068: 284-296 [Abstract] [Full Text]  
• Dharnidharka, V. R., Vincenti, F. (2005). Costimulation Blockade with Belatacept in Renal Transplantation.. NEJM 353: 2085-2086 [Full Text]